SEC Form 4 · accession 0001697422-26-000002
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher R. Fenimore
Officer — EVP Finance CFO
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 18, 2026 | M | 6,283 | $381.92 | A | 24,583 | D | |
| Common Stock | Aug 18, 2026 | F | 4,599 | $813.47 | D | 19,984 | D | |
| Common Stock | holding | — | — | — | 1,574 | I | By 401(k) Plan | |
| Common StockF1 | holding | — | — | — | 1,897 | I | By Trust | |
| Common Stock | holding | — | — | — | 25 | I | by Trust for Daugh | |
| Common Stock | holding | — | — | — | 25 | I | by Trust for Son |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $381.92 | Aug 18, 2026 | M | 6,283 | D | — | Dec 16, 2026 | Common Stock | 6,283 | 6,000 | D |
Explanation of responses
- F1These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
- F2The stock option award vested in four equal annual installments, commencing one year after the date of grant.